Charlotte Robinson

DocwireNews

The potassium binder sodium zirconium cyclosilicate (SZC) may be an option for the prevention or management of hyperkalemia in hemodialysis (HD) patients, but data regarding its safety and efficacy among Asian HD patients beyond phase 3 trials have been limited. Thus, Behram Khan reported on real-world use of SZC in a cohort of Asian HD patients at the International Society of Nephrology World Congress of Nephrology 2024.A total of 293 patients who received maintenance HD at community-based dialysis centers in Singapore were the subject of a clinical audit. They received SZC for either prevention or management of hyperkalemia during anticipated interruptions to dialysis, such as when traveling.Among those receiving treatment for hyperkalemia (n=147), serum potassium (K+) prior to starting SZC and at the end point were compared using a paired t test. Changes in K+ from baseline to end point were compared across different categories within each demographic and health-related variables using either a t test or one-way analysis of variance. Patients who had adverse events after starting SZC or were deceased during the audit were reviewed so that an informative account could be provided.Among patients who received SZC for hyperkalemia treatment, use of SZC was associated with a significant reduction in serum potassium (0.812 mmol/L). Patients who were not of Chinese, Malay, or Indian ethnicity saw a nominal reduction in K+ of 0.7 mmol/L; the small sample size of this subgroup accounts for this. Individuals of Chinese, Malay, and Indian ethnicities represented more than 95% of the sample and showed a significant reduction in K+ levels (P&lt;.001). Other studies of SZC demonstrated similar efficacy across ethnicities. Patients who received SZC for hyperkalemia treatment or prevention had a significantly reduced mortality rate. However, this reduction in mortality may have inherent biases and confounders, due to the retrospective clinical audit study design.The efficacy of SZC in the real-world setting was similar to that found in previous trials. &ldquo;Overall, SZC was safe and effective among the audited patients,&rdquo; Khan concluded. &ldquo;The novel use of SZC to manage serum potassium when HD sessions are missed, such as during traveling, warrants further investigation due to potentially significant life-saving implications.&rdquo;Source: <a href="https://doi.org/10.1016/j.ekir.2024.02.018" target="_blank" rel="noopener">KI Reports</a>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

SZC for Hyperkalemia Management in Asian Hemodialysis Patients

WCN 2024

Researchers reported on real-world use of the potassium binder sodium zirconium cyclosilicate (SZC) for hyperkalemia in a cohort of Asian hemodialysis patients.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe